PD-L1 CPS es el biomarcador predictivo primario para pembrolizumab en H recurrente/metastásico...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-PDL1-CPS-HNSCC |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-05-07 | actionability review required |
| Enfermedades | DIS-HNSCC |
| Fuentes | SRC-ESMO-HNSCC-2020 SRC-NCCN-HNSCC-2025 |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-PDL1-CPS |
|---|---|
| Enfermedad | DIS-HNSCC |
| El nivel de ESCAT | IA |
| Combinaciones recomendadas | pembrolizumab monotherapy (CPS≥20 1L per SRC-NCCN-HNSCC-2025, SRC-ESMO-HNSCC-2020), pembrolizumab + platinum + 5-FU (CPS≥1 1L per SRC-NCCN-HNSCC-2025) |
| Resumen de las pruebas | PD-L1 CPS is the primary predictive biomarker for pembrolizumab in recurrent/metastatic HNSCC (KEYNOTE-048). Two threshold-stratified eligibility bands: CPS ≥1 — pembrolizumab + platinum + 5-FU 1L (superior to EXTREME regimen in CPS≥1 population); CPS ≥20 — pembrolizumab monotherapy 1L (preferred over chemo in high-expressors; mOS 14.9 mo). Both are FDA-approved and NCCN/ESMO Category 1 recommendations. Testing by IHC 22C3. Threshold selection is performed by the algorithm layer (ALGO-HNSCC-RM-1L); this BMA entry surfaces ESCAT tier context for tumor-board discussion only. |
Notas
Variant_qualifier null — dual-threshold gating (CPS≥1 for combo, CPS≥20 for mono) is enforced by the algorithm/indication layer, not this BMA cell. KEYNOTE-048 source stub not yet ingested; citing NCCN/ESMO as proxies.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.